GlassScriptPhysician profile
Brooke Wethington
NPI 1427593680
$2,432.31
in general payments reported to CMS, 2019-2025
31 companies · $79.61 in 2025
The $79.61 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,945 · 2022: $352 · 2024: $56.28 · 2025: $79.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $357.37 | 2021-2022 | |
| Amarin Pharma, INC. | $212.13 | 2021 | |
| Novo Nordisk INC | $206.09 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $157.46 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.06 | 2021-2022 | |
| Glaxosmithkline, LLC. | $141.54 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.48 | 2021-2022 | |
| Pfizer INC. | $91.66 | 2021 | |
| Amgen INC. | $89.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $77.44 | 2021-2022 | |
| Lilly USA, LLC | $72.76 | 2021-2024 | Mounjaro |
| Grifols USA, LLC | $68.89 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.34 | 2021-2022 | |
| Exact Sciences Corporation | $60.18 | 2025 | The Cologuard Plus Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $52.27 | 2021-2022 | |
| Daiichi Sankyo INC. | $51.47 | 2021-2022 | |
| Mylan Specialty L.P. | $40.25 | 2021-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $38.71 | 2021 | |
| Esperion Therapeutics, INC. | $35.03 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $32.52 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.36 | 2021 | |
| Dexcom, INC. | $24.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.40 | 2021 | |
| Eisai INC. | $21.78 | 2021 | |
| Medicure Pharma INC. | $20.40 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.96 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.11 | 2021 | |
| Insulet Corporation | $14.11 | 2021 | |
| Smith+Nephew, INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Wethington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.